|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ABII 10-Q filed Aug 14, 2008. Other Deferred Revenue Other deferred revenue primarily consists of upfront payments earned from our co-promotion and license agreements. Such deferred revenue is recognized as earned ratably over the life of each agreement. This excerpt taken from the ABII 10-Q filed May 15, 2008. Other Deferred Revenue Other deferred revenue primarily consists of upfront payments earned from our co-promotion and license agreements. Such deferred revenue is recognized as earned ratably over the life of each agreement. These excerpts taken from the ABII 10-K filed Mar 31, 2008. Other Deferred Revenue Other deferred revenue primarily consists of upfront payments earned from our co-promotion agreement with AstraZeneca and our license agreement with Taiho Pharmaceutical Co., Ltd. Such deferred revenue is recognized as earned ratably over the life of each agreement.
51
Table of ContentsOther Deferred Revenue SIZE="2">Other deferred revenue primarily consists of upfront payments earned from our co-promotion agreement with AstraZeneca and our license agreement with Taiho Pharmaceutical Co., Ltd. Such deferred revenue is recognized as earned ratably over
51 Table of ContentsThis excerpt taken from the ABII 10-Q filed Dec 20, 2007. Other Deferred Revenue Other deferred revenue primarily consists of upfront payments earned from our co-promotion agreement with AstraZeneca and our license agreement with Taiho Pharmaceutical Co., Ltd. Such deferred revenue is recognized as earned ratably over the life of each agreement. This excerpt taken from the ABII 8-K filed Nov 8, 2007. Other Deferred Revenue Other deferred revenue primarily consists of upfront payments earned from our co-promotion agreement with AstraZeneca and our license agreement with Taiho Pharmaceutical Co., Ltd. Such deferred revenue is recognized as earned ratably over the life of each agreement. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ABII: |
| |||||||
